C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

Alzheimer's and Dementia

Volumn 11, Issue 12, 2015, Pages 1461-1469

  De Vos, Ann ^a   Jacobs, Dirk ^a   Struyfs, Hanne ^b   Fransen, Erik ^c   Andersson, Kerstin ^d   Portelius, Erik ^d   Andreasson, Ulf ^d   De Surgeloose, Didier ^e   Hernalsteen, Daniëlle ^e   Sleegers, Kristel ^b,f   Robberecht, Caroline ^b,f   Van Broeckhoven, Christine ^b,f   Zetterberg, Henrik ^d,g   Blennow, Kaj ^d   Engelborghs, Sebastiaan ^b,h   Vanmechelen, Eugeen ^a  

^a ADX NEUROSCIENCES   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

Author keywords

Alzheimer's disease; Amyloid; CSF biomarker; ELISA; Mild cognitive impairment; Neurogranin; Plasma biomarker; Prognostic biomarker; Ratio amyloid ; tau; secretase

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; NEUROGRANIN; PLASMA PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DEMENTIA; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; VALIDATION STUDY; AGED; BLOOD; CEREBROSPINAL FLUID; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROGRANIN; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84952317004     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.05.012     Document Type: Article

References (44)

1. J.L. Molinuevo, K. Blennow, B. Dubois, S. Engelborghs, P. Lewczuk, A. Perret-Liaudet, and et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 10 2014 808 817
2. P.T. Nelson, H. Braak, and W.R. Markesbery Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship J Neuropathol Exp Neurol 68 2009 1 14
3. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, and et al. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment Ann Neurol 30 1991 572 580
4. K. Blennow, N. Bogdanovic, I. Alafuzoff, R. Ekman, and P. Davidsson Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele J Neural Transm 103 1996 603 618
5. F.J. Díez-Guerra Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity IUBMB Life 62 2010 597 606
6. P. Davidsson, M. Puchades, and K. Blennow Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing Electrophoresis 20 1999 431 437
7. M.G. Harrington, A.N. Fonteh, E. Oborina, P. Liao, R.P. Cowan, G. McComb, and et al. The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid Cerebrospinal Fluid Res 6 2009 10
8. S.E. Schutzer, T. Liu, B.H. Natelson, T.E. Angel, A.A. Schepmoes, S.O. Purvine, and et al. Establishing the proteome of normal human cerebrospinal fluid PLoS One 5 2010 e10980
9. P. Davidsson, and K. Blennow Neurochemical dissection of synaptic pathology in Alzheimer's disease Int Psychogeriatr 10 1998 11 23
10. P.H. Reddy, G. Mani, B.S. Park, J. Jacques, G. Murdoch, W. Whetsell Jr., and et al. Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunction J Alzheimers Dis 7 2005 103 117 discussion 173-80
11. A. Thorsell, M. Bjerke, J. Gobom, E. Brunhage, E. Vanmechelen, N. Andreasen, and et al. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease Brain Res 1362 2010 13 22
12. H. Kvartsberg, F.H. Duits, M. Ingelsson, N. Andreasen, A. Öhrfelt, K. Andersson, and et al. Cerebrospinal fluid levels of the synaptic protein neurogranin predict cognitive decline in prodromal Alzheimer's disease Alzheimers Dement 11 2015 1180 1190
13. T. Farrah, E.W. Deutsch, G.S. Omenn, D.S. Campbell, Z. Sun, J.A. Bletz, and et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas Mol Cell Proteomics 10 2011 M110.006353
14. R.P. Lange, A. Everett, P. Dulloor, F.K. Korley, C. Bettegowda, C. Blair, and et al. Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas Cancer Invest 32 2014 423 429
15. J.E. Meredith Jr., S. Sankaranarayanan, V. Guss, A.J. Lanzetti, F. Berisha, R.J. Neely, and et al. Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease PLoS One 8 2013 e76523
16. H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow, J. Randall, and et al. Plasma tau levels in Alzheimer's disease Alzheimers Res Ther 5 2013 9
17. P. Lewczuk, N. Lelental, P. Spitzer, J.M. Maler, and J. Kornhuber Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: Validation of two novel assays J Alzheimers Dis 43 2015 183 191
18. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, and et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
19. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., C.H. Kawas, and et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
20. S. Van der Mussele, E. Fransen, H. Struyfs, J. Luyckx, P. Mariën, J. Saerens, and et al. Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: A longitudinal study J Alzheimers Dis 42 2014 1239 1250
21. P. Scheltens, D. Leys, F. Barkhof, D. Huglo, H.C. Weinstein, P. Vermersch, and et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates J Neurol Neurosurg Psychiatry 55 1992 967 972
22. V.C. Cullen, R.A. Fredenburg, C. Evans, P.R. Conliffe, and M.E. Solomon Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid AAPS J 14 2012 510 518
23. O. Uspenskaia, M. Liebetrau, J. Herms, A. Danek, and G.F. Hamann Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels BMC Neurosci 5 2004 37
24. Y. Guo, S.W. Qumu, O.A. Nacar, J.Y. Yang, J. Du, D. Belen, and et al. Human brain arteriovenous malformations are associated with interruptions in elastic fibers and changes in collagen content Turk Neurosurg 23 2013 10 15
25. M. Ponticos, and B.D. Smith Extracellular matrix synthesis in vascular disease: Hypertension, and atherosclerosis J Biomed Res 28 2014 25 39
26. N.B. Fedorov, P. Pasinelli, A.B. Oestreicher, P.N. DeGraan, and K.G. Reymann Antibodies to postsynaptic PKC substrate neurogranin prevent long-term potentiation in hippocampal CA1 neurons Eur J Neurosci 7 1995 819 822
27. G.M. Ramakers, P.N. De Graan, I.J. Urban, D. Kraay, T. Tang, P. Pasinelli, and et al. Temporal differences in the phosphorylation state of pre- and postsynaptic protein kinase C substrates B-50/GAP-43 and neurogranin during long-term potentiation J Biol Chem 270 1995 13892 13898
28. Z. Jin, Z. Fu, J. Yang, J. Troncosco, A.D. Everett, and J.E. Van Eyk Identification and characterization of citrulline-modified brain proteins by combining HCD and CID fragmentation Proteomics 13 2013 2682 2691
29. O.F. Laterza, V.R. Modur, D.L. Crimmins, J.V. Olander, Y. Landt, J.M. Lee, and et al. Identification of novel brain biomarkers Clin Chem 52 2006 1713 1721
30. D.V. Gnatenko, J.J. Dunn, S.R. McCorkle, D. Weissmann, P.L. Perrotta, and W.F. Bahou Transcript profiling of human platelets using microarray and serial analysis of gene expression Blood 101 2003 2285 2293
31. L.R. Devireddy, and M.R. Green Transcriptional program of apoptosis induction following interleukin 2 deprivation: Identification of RC3, a calcium/calmodulin binding protein, as a novel proapoptotic factor Mol Cell Biol 23 2003 4532 4541
32. J.T. Chi, H.Y. Chang, G. Haraldsen, F.L. Jahnsen, O.G. Troyanskaya, D.S. Chang, and et al. Endothelial cell diversity revealed by global expression profiling Proc Natl Acad Sci U S A 100 2003 10623 10628
33. G. Sengoelge, W. Winnicki, A. Kupczok, A. von Haeseler, M. Schuster, W. Pfaller, and et al. A SAGE based approach to human glomerular endothelium: Defining the transcriptome, finding a novel molecule and highlighting endothelial diversity BMC Genomics 15 2014 725
34. K.M. Henkins, S. Sokolow, C.A. Miller, H.V. Vinters, W.W. Poon, L.B. Cornwell, and et al. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses Brain Pathol 22 2012 826 833
35. H.C. Tai, A. Serrano-Pozo, T. Hashimoto, M.P. Frosch, T.L. Spires-Jones, and B.T. Hyman The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system Am J Pathol 181 2012 1426 1435
36. A.M. Pooler, W. Noble, and D.P. Hanger A role for tau at the synapse in Alzheimer's disease pathogenesis Neuropharmacology 76 Pt A 2014 1 8
37. K.R. Wildsmith, S.P. Schauer, A.M. Smith, D. Arnott, Y. Zhu, J. Haznedar, and et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics Mol Neurodegener 9 2014 22
38. C. Rosén, U. Andreasson, N. Mattsson, J. Marcusson, L. Minthon, N. Andreasen, and et al. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease Neuromolecular Med 14 2012 65 73
39. L. Chávez-Gutiérrez, L. Bammens, I. Benilova, A. Vandersteen, M. Benurwar, M. Borgers, and et al. The mechanism of γ-secretase dysfunction in familial Alzheimer disease EMBO J 31 2012 2261 2274
40. N. Kakuda, M. Shoji, H. Arai, K. Furukawa, T. Ikeuchi, K. Akazawa, and et al. Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease EMBO Mol Med 4 2012 344 352
41. J. Wiltfang, H. Esselmann, M. Bibl, M. Hüll, H. Hampel, H. Kessler, and et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load J Neurochem 101 2007 1053 1059
42. M. Bjerke, E. Portelius, L. Minthon, A. Wallin, H. Anckarsäter, R. Anckarsäter, and et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid Int J Alzheimers Dis 2010 2010
43. J. Pannee, E. Portelius, M. Oppermann, A. Atkins, M. Hornshaw, I. Zegers, and et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls J Alzheimers Dis 33 2013 1021 1032
44. A. Leinenbach, J. Pannee, T. Dülffer, A. Huber, T. Bittner, U. Andreasson, and et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid Clin Chem 60 2014 987 994